Related references
Note: Only part of the references are listed.Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
Ilkka Tikkanen et al.
DIABETES CARE (2015)
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
Bernard Zinman et al.
CARDIOVASCULAR DIABETOLOGY (2014)
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
David Z. I. Cherney et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
Treatment of Hypertension and Metabolic Syndrome: Lowering Blood Pressure Is Not Enough for Organ Protection, New Approach-Arterial Destiffening
Reuven Zimlichman
CURRENT HYPERTENSION REPORTS (2014)
Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2014)
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
J. Bolinder et al.
DIABETES OBESITY & METABOLISM (2014)
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes
J. Dziuba et al.
DIABETES OBESITY & METABOLISM (2014)
Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
Marko Skrtic et al.
DIABETOLOGIA (2014)
Uric acid and risk of heart failure: a systematic review and meta-analysis
He Huang et al.
EUROPEAN JOURNAL OF HEART FAILURE (2014)
Index of central obesity as a parameter to replace waist circumference for the definition of metabolic syndrome in predicting cardiovascular disease
Wenshu Luo et al.
JOURNAL OF CARDIOVASCULAR MEDICINE (2014)
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Aurora Merovci et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
Richard E. Gilbert
KIDNEY INTERNATIONAL (2014)
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
Donald E. Kohan et al.
KIDNEY INTERNATIONAL (2014)
Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
Alan Sinclair et al.
BMC ENDOCRINE DISORDERS (2014)
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
Martin Ridderstrale et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
Anthony H. Barnett et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial
Bruce Neal et al.
AMERICAN HEART JOURNAL (2013)
Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes A Systematic Review and Meta-analysis
Despoina Vasilakou et al.
ANNALS OF INTERNAL MEDICINE (2013)
Hyperglycemia Promotes Myelopoiesis and Impairs the Resolution of Atherosclerosis
Prabhakara R. Nagareddy et al.
CELL METABOLISM (2013)
The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988-2010
Sarah Stark Casagrande et al.
DIABETES CARE (2013)
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
H. J. Lambers Heerspink et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
J-F Yale et al.
DIABETES OBESITY & METABOLISM (2013)
Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial
Linda G. Mellbin et al.
EUROPEAN HEART JOURNAL (2013)
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Lars Ryden et al.
EUROPEAN HEART JOURNAL (2013)
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
Atsuo Tahara et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Incorporating Lag Time to Benefit Into Prevention Decisions for Older Adults
Sei J. Lee et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Adipose tissue heterogeneity: Implication of depot differences in adipose tissue for obesity complications
Mi-Jeong Lee et al.
MOLECULAR ASPECTS OF MEDICINE (2013)
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
William T. Cefalu et al.
LANCET (2013)
The Cardiovascular Safety of Diabetes Drugs - Insights from the Rosiglitazone Experience
William R. Hiatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells-Renoprotection in Diabetic Nephropathy?
Usha Panchapakesan et al.
PLOS ONE (2013)
Serum Uric Acid Is Not an Independent Risk Factor for Premature Coronary Artery Disease
Sara Zand et al.
CARDIORENAL MEDICINE (2013)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Tim Heise et al.
DIABETES THERAPY (2013)
Adiposopathy, Diabetes Mellitus, and Primary Prevention of Atherosclerotic Coronary Artery Disease: Treating Sick Fat Through Improving Fat Function with Antidiabetes Therapies
Harold E. Bays
AMERICAN JOURNAL OF CARDIOLOGY (2012)
Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter Inhibitor, as Add-On to Meiformin in Subjects With Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2012)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
Jan Bolinder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Association of uric acid with mortality in patients with stable coronary artery disease
Gjin Ndrepepa et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2012)
Sodium-Glucose Cotransporter Inhibition Prevents Oxidative Stress in the Kidney of Diabetic Rats
Horacio Osorio et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2012)
Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations
Wendy L. Bennett et al.
ANNALS OF INTERNAL MEDICINE (2011)
Postprandial Hyperglycemia and Glycemic Variability Should we care?
Eberhard Standl et al.
DIABETES CARE (2011)
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
S. Sha et al.
DIABETES OBESITY & METABOLISM (2011)
Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
Gian Paolo Fadini et al.
VASCULAR PHARMACOLOGY (2011)
Visceral Adiposity Index A reliable indicator of visceral fat function associated with cardiometabolic risk
Marco C. Amato et al.
DIABETES CARE (2010)
In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans
M. Obermeier et al.
DRUG METABOLISM AND DISPOSITION (2010)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Clifford J. Bailey et al.
LANCET (2010)
Glucose Control by the Kidney: An Emerging Target in Diabetes
Olivera Marsenic
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Uric Acid and Long-term Outcomes in CKD
Magdalena Madero et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
B. Komoroski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Solute carrier family 2, member 9 and uric acid homeostasis
Chris Cheeseman
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2009)
Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association
Jay S. Skyler et al.
DIABETES CARE (2009)
The growing burden of diabetes mellitus in the US elderly population
Frank A. Sloan et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Cardiovascular disease and type 2 diabetes mellitus: A multifaceted symbiosis
O. E. Johansen
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2007)
Abdominal obesity and metabolic syndrome
Jean-Pierre Despres et al.
NATURE (2006)
Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies
R Huxley et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
H Rahmoune et al.
DIABETES (2005)
Share Paper
